دورية أكاديمية

PTEN Promoter Variants Are Not Associated With Common Cancers: Implications for Multigene Panel Testing.

التفاصيل البيبلوغرافية
العنوان: PTEN Promoter Variants Are Not Associated With Common Cancers: Implications for Multigene Panel Testing.
المؤلفون: Black, Mary Helen, Shuwei Li, Pesaran, Tina, LaDuca, Holly, Karam, Rachid, Clifford, Jacob, Smith, Brandon, Pilarski, Robert
المصدر: JCO Precision Oncology; 2017, Vol. 1, p1-7, 18p
مصطلحات موضوعية: CANCER genetics, PTEN protein, PROMOTERS (Genetics), NUCLEOTIDE sequencing, GENETIC mutation
مستخلص: Purpose PTEN mutations are associated with breast, colon, endometrial, kidney, and thyroid cancers. Most PTEN promoter alterations, however, are characterized as variants of unknown significance, and their contribution to cancer risk is unclear. Materials and Methods Personal and family histories of 88,333 patients undergoing PTEN analysis as part of multigene panel testing (MGPT) were retrospectively reviewed. Cases (n=59,784)were individuals with personal history of PTEN-related cancer. Controls (n=28,549) had no personal history of cancer. Individuals were categorized as positive for one or more mutations(PATHO), without mutations but carrying one or morepromoter variant(PROM), or negative for alterations (WT). Multivariable logistic regression was used to assess PTEN associations with phenotypes, adjusted for race/ethnicity, age, sex, and MGPT. Results Overall, 79 (0.09%) patients were PATHO and 791 (0.9%) were PROM carriers. Compared with WT, PATHOs were 2.30 (95% CI, 1.19 to 4.72) times as likely to have breast, 7.23 (95% CI, 2.74 to 19.14) times as likely to have bilateral/multiple primary breast, and 7.56 (95% CI, 1.97 to 23.98) times as likely to have uterine/endometrial cancer. PROMs were not significantly more likely than WT to have cancer (all 0.84 < odds ratio < 1.15; P > .05). Conclusion PTEN promoter variants were not associated with cancer. These results do not support the inclusion of PTEN promoter sequencing in MGPT. [ABSTRACT FROM AUTHOR]
Copyright of JCO Precision Oncology is the property of American Society of Clinical Oncology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index